Clinical Trials Logo

Mucopolysaccharidosis IVA clinical trials

View clinical trials related to Mucopolysaccharidosis IVA.

Filter by:
  • None
  • Page 1

NCT ID: NCT01858103 Approved for marketing - MPS IVA Clinical Trials

BMN 110 US Expanded Access Program

Start date: n/a
Phase: N/A
Study type: Expanded Access

The Expanded Access Program (EAP) is an open-label, multicenter program to: 1. Provide patients who have been diagnosed with Mucopolysaccharidosis IVA (MPS IVA) access to BMN 110 until commercial product is available 2. Collect additional information on the safety and tolerability of BMN 110 administration in patients with MPS IVA Patients enrolled in the EAP will receive 2.0 mg/kg intravenous infusions of BMN 110 every week during the program.

NCT ID: NCT01697319 Terminated - MPS IVA Clinical Trials

Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation

Start date: August 2012
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the effect of 2.0 mg/kg/week BMN 110 in a patient population that has limited ambulation, in a period of up to 144 weeks.

NCT ID: NCT01609062 Terminated - MPS IVA Clinical Trials

Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome

Start date: April 2012
Phase: Phase 2
Study type: Interventional

The primary objective of this study was to evaluate the safety of a 2.0 mg/kg/week and a 4.0 mg/kg/week of BMN 110 in patients with Morquio A syndrome for up to 196 weeks. Secondary objectives were to investigate the effect of the two doses on exercise capacity for up to 196 weeks. In addition, the pharmacokinetic (PK) parameters of both doses of BMN 110 was assessed.

NCT ID: NCT01515956 Completed - MPS IVA Clinical Trials

Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Start date: October 2011
Phase: Phase 2
Study type: Interventional

This open-label Phase 2 study will evaluate the safety and efficacy of weekly 2.0 mg/kg/wk infusions of BMN 110 in pediatric patients, less than 5 years of age at the time of administration of the first dose of study drug, diagnosed with MPS IVA (Morquio A Syndrome) for up to 208 weeks.

NCT ID: NCT01242111 Terminated - Morquio A Syndrome Clinical Trials

A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Start date: November 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This multicenter, open-label extension study is designed to assess long-term efficacy and safety of 2.0 milligrams (mg)/kilogram(kg)/week of BMN 110 in patients diagnosed with Mucopolysaccharidosis IVA (MPS IVA). Patients with MPS IVA, who enrolled in a prior BioMarin sponsored clinical study of BMN 110 (NCT00884949; Study Identification Number MOR-002), were eligible to enroll in this study (except patients who enrolled in NCT01275066; Study Identification Number MOR-004).

NCT ID: NCT00787995 Terminated - Morquio A Syndrome Clinical Trials

A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)

Start date: October 2008
Phase: N/A
Study type: Observational

This multicenter, multinational, longitudinal study will quantify endurance and respiratory function in subjects diagnosed with MPS IVA and will better characterize the spectrum of symptoms and biochemical abnormalities in MPS IVA disease over time.